Table 2. The characteristics of changes in high-risk factors in preoperative and postoperative evaluations in all patients and patients suitable for lobectomy.

		Preoperative evaluation	Postoperative evaluation	p
All patients (n- 96)	Tumor size (mm)	11.70 (12.00)	12.00 (11.75)	0.336
	<10 mm	41 (42.7)	38 (39.6)	0.278
	11-20 mm	34 (35.4)	37 (38.5)
	21-39 mm	16 (16.7)	18 (18.8)
	>40 mm	5 (5.2)	3 (3.1)
	Multifocality	18 (18.8)	45 (46.9)	<0.001
	Contralateral multifocality	9 (9.4)	36 (37.5)	<0.001
	ETE	12 (12.5)	10 (10.4)	0.824
	Central lymph node metastasis	31 (32.3)	46 (47.9)	0.014
	Metastatic central lymph node count	0.00 (1.00)	0.00 (3.00)	<0.001
	Metastatic central lymph node size (mm)	0.00 (5.00)	0.00 (2.50)	0.655
	Number of patients eligible for lobectomy	51 (53.1)	24 (25.0)	<0.001
Lobectomy eligible patients (n- 51)	Tumor Size (mm)	11.00 (12.00)	11.00 (13.00)	0.483
	<10 mm	25 (49)	23 (45.1)	0.337
	11-20 mm	16 (31.4)	17 (33.3)
	21-39 mm	7 (13.7)	10 (19.6)
	>40 mm	3 (5.9)	1 (2)
	Multifocality	4 (7.8)	19 (37.3)	<0.001
	Contralateral multifocality	0 (0)	13 (25.5)	<0.001
	ETE	0 (0)	3 (5.9)	0.083
	Central lymph node metastasis	0 (0)	16 (31.4)	<0.001
	Metastatic central lymph node count	0.00 (0.00)	0.00 (1.00)	<0.001
	Metastatic central lymph node size (mm)	0.00 (0.00)	0.00 (0.80)	<0.001